Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
- Sponsor
- Siriraj Hospital
- Study ID
- NCT01922154
- Phase
- PHASE4
- Status
- Completed
Conditions
- Glaucoma, Neovascular
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- intravitreal ranibizumab — DRUGThe patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
- Trabeculectomy with mitomycinC — PROCEDUREAll participant underwent trabeculectomy with mitomycinC , which is the standard procedure for refractory glaucoma.
Study Details
To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).
Key Dates
- First listed
- Aug 14, 2013
- Start date
- Feb 28, 2009
- Status verified
- Jul 2021
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
Study Design
- Enrollment
- 15 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: intravitreal ranibizumabRanibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
Primary Outcome Measure
The change of intraocular pressure (IOP) [ Time Frame: Change of IOP between before trabeculectomy and at last visit ]